<?xml version="1.0" encoding="UTF-8"?>
<p id="Par53">Even when the product discovery and CMC assets are managed by the same company, the response to a pandemic outbreak is likely to be a difficult challenge and would require changes to existing governance and decision-making systems. The large effort required for business and legal departments to execute the necessary agreements could delay the initiation of the first stages of CMC development and hence the critical path to clinical trial initiation. In this respect, open material transfer agreements are starting to be considered for tech transfer in the academic setting.</p>
